Lung cancer and cellular aging markers — prospective cohort
Identification of Aging Biomarkers for Better Tailoring of Cancer Treatment in Older Patients With Lung Cancer: a Multicenter Clinico-biological Cohort Study
We will test whether aging and senescence markers measured in blood and tissue can help predict outcomes for people aged 70 and older who are having curative surgery for early to locally advanced non-small cell lung cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 385 (estimated) |
| Ages | 70 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Créteil, Île-de-France Region) |
| Trial ID | NCT06923618 on ClinicalTrials.gov |
What this trial studies
This prospective cohort enrolls patients aged 70 and older with clinical or histologic stage I–IIIA non‑small cell lung cancer scheduled for curative-intent surgery. Blood samples and surgical tissue will be collected to measure methylome-based epigenetic age, telomere integrity, inflammaging markers, and senescent cells. Biomarker data will be combined with geriatric assessments and clinical follow-up to link markers with outcomes such as early death, major complications, unplanned hospitalization, treatment toxicity, and quality of life. The study aims to determine whether these quantitative aging measures improve prognostic stratification and support surgical decision-making for older patients.
Who should consider this trial
Good fit: People aged 70 or older with clinically or histologically suspected stage I–IIIA non‑small cell lung cancer who are scheduled for curative-intent surgery and can give informed consent.
Not a fit: Patients younger than 70, those with metastatic disease or synchronous non‑lung cancers within six months, or patients unable to consent are unlikely to benefit from the study's results.
Why it matters
Potential benefit: If successful, these markers could help doctors identify older patients at high risk of complications or early death so they can tailor treatment, monitoring, and supportive care.
How similar studies have performed: Related research on epigenetic clocks, telomere measures, and inflammaging has shown promising links to aging and adverse outcomes, but these biomarkers are not yet established for routine clinical prognosis in surgical lung cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 70 years and over * Local or locally advanced (Clinic stage I-IIIA) NSCLC (clinically (or radiologically) suspected or histologically proven) * Surgical Curative Intent * Signed informed Consent (or signed by the curator or tutorship) * Affiliated to social security administrative care service Exclusion Criteria: * Synchronous cancer (histologically proven or strongly suspected non-lung cancer in the 6 months prior to inclusion (excluding basal cell cancer and prostate cancer with local treatment (radiotherapy or surgery) or active surveillance without systemic treatment (chemotherapy, hormone therapy)). * Subject deprived of liberty by judicial or administrative decision or patient under guardianship * Subject unable to understand the purpose and conditions of the study and unable to give consent
Where this trial is running
Créteil, Île-de-France Region
- Henri Mondor Hospital — Créteil, Île-de-France Region, France (Recruiting)
Study contacts
- Principal investigator: Florence CANOUÏ-POITRINE, PhD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Florence CANOUÏ-POITRINE, PhD
- Email: florence.canoui-poitrine@aphp.fr
- Phone: 01 49 81 36 74
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.